Eli Lilly (LLY) was upgraded to Buy from Neutral at Goldman Sachs. The analyst sees a "compelling entry point into the sector's premier topline grower" and slightly lowered the price target to $888 from $892. Ben Watson looks at the technical patterns and trends developing in the health care giant.